Novocure Ltd (NVCR)

[herbied47]

Is the glass half full here? Or totally empty? A few objective data points to ponder:
• $1B in cash. To borrow from Jay-Z, NVCR may have 99 problems, but cash ain’t one.
• $500M/ yr GBM business that sustains itself, generating more cash that it consumes
• Every human clinical trial NVCR has ever run has succeeded at hitting its primary endpoint with statistical significance
• 3 ph3 trials will report results over the next ~15 mos: Ovarian, Metis, Pancreatic. All 3 of these trials have straightforward, simple design in cancers with little competitive therapies. If even one of these trials succeeds, it should become a multi-billion dollar blockbuster business line
• In the biotech world, delivering successful clinical trials is hard. Even if NVCR management is weak, if NVCR delivers successful trial wins, somebody will see the value and NVCR might become an acquisition target.